The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V76085 | SARS-CoV-2-IN-62 | 2350285-18-4 | SARS-CoV-2-IN-62 (Compound R3b)? is an inhibitor (blocker/antagonist) of SARS-CoV-2 replication and has low cytotoxic effect. |
|
V76082 | SARS-CoV-2-IN-63 | 2350285-21-9 | SARS-CoV-2-IN-63 (Compound R3e)? is a SARS-CoV-2 replication inhibitor (antagonist) with low cytotoxic effect. |
|
V81373 | SARS-CoV-2-IN-64 | SARS-CoV-2-IN-64 (compound 9) is a chenodeoxycholic acid analogue and a potent inhibitor of the SARS-CoV-2 spike glycoprotein. | |
|
V79481 | SARS-CoV-2-IN-65 | SARS-CoV-2-IN-65 (compound 2f (81)) is a potent, orally bioactive, reversible inhibitor of SARS-CoV-2 entry. | |
|
V76083 | SARS-CoV-2-IN-66 | 1807620-38-7 | SARS-CoV-2-IN-66 (1) is a vitamin K analogue and an inhibitor (blocker/antagonist) of SARS-CoV-2 with EC50 of 70.8 μM in infected VeroE6/TMPRSS2 cells. |
|
V78818 | SARS-CoV-2-IN-67 | SARS-CoV-2-IN-67 (Compound 16) is a vitamin K analogue with anti-SARS-CoV-2 activity (EC50= 64.8 μM in VeroE6/TMPRSS2 cells). | |
|
V76092 | SARS-CoV-2-IN-68 | 2682897-84-1 | SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor (antagonist) with potent antiviral effect. |
|
V76095 | SARS-CoV-2-IN-69 | 78471-90-6 | SARS-CoV-2-IN-69 (Compound 7E) is a non-covalent SARS-CoV-2 inhibitor (antagonist) with EC50 of 7.4 μM. |
|
V53133 | SARS-CoV-2-IN-7 | 2570461-66-2 | SARS-CoV-2-IN-7 inhibits viral replication with a nanomolar IC50 (844 nM) in SARS-CoV-2-infected Vero E6 cells. |
|
V85895 | SARS-CoV-2-IN-71 | ||
|
V85123 | SARS-CoV-2-IN-72 | ||
|
V84621 | SARS-CoV-2-IN-73 | ||
|
V84501 | SARS-CoV-2-IN-74 | ||
|
V84562 | SARS-CoV-2-IN-75 | 2738323-08-3 | |
|
V84413 | SARS-CoV-2-IN-76 (S-Adenosyl-DL-homocysteine) | 58976-18-4 | |
|
V84521 | SARS-CoV-2-IN-77 | ||
|
V83846 | SARS-CoV-2-IN-78 | 38716-45-9 | |
|
V83899 | SARS-CoV-2-IN-79 | ||
|
V81374 | SARS-CoV-2-IN-8 | SARS-CoV-2-IN-8 is a major protease inhibitor of SARS-CoV-2 with IC50 of 0.75 μM. | |
|
V83456 | SARS-CoV-2-IN-80 | 57341-12-5 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
